Cargando…

Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3 years study from China

BACKGROUND: Patients with diabetes and triple-vessel disease (TVD) are associated with a high risk of events. The choice of treatment strategies remains a subject of discussion. In the real-world, we aim to compare the outcomes of medical therapy (MT), coronary artery bypass grafting (CABG), and per...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xueyan, Xu, Lianjun, Jiang, Lin, Tian, Jian, Zhang, Yin, Wang, Dong, Sun, Kai, Xu, Bo, Zhao, Wei, Hui, Rutai, Gao, Runlin, Song, Lei, Yuan, Jinqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798318/
https://www.ncbi.nlm.nih.gov/pubmed/33430864
http://dx.doi.org/10.1186/s12933-020-01193-3
_version_ 1783635038384947200
author Zhao, Xueyan
Xu, Lianjun
Jiang, Lin
Tian, Jian
Zhang, Yin
Wang, Dong
Sun, Kai
Xu, Bo
Zhao, Wei
Hui, Rutai
Gao, Runlin
Song, Lei
Yuan, Jinqing
author_facet Zhao, Xueyan
Xu, Lianjun
Jiang, Lin
Tian, Jian
Zhang, Yin
Wang, Dong
Sun, Kai
Xu, Bo
Zhao, Wei
Hui, Rutai
Gao, Runlin
Song, Lei
Yuan, Jinqing
author_sort Zhao, Xueyan
collection PubMed
description BACKGROUND: Patients with diabetes and triple-vessel disease (TVD) are associated with a high risk of events. The choice of treatment strategies remains a subject of discussion. In the real-world, we aim to compare the outcomes of medical therapy (MT), coronary artery bypass grafting (CABG), and percutaneous coronary intervention (PCI) treatment strategies in patients with diabetes and TVD. METHODS: A total of 3117 consecutive patients with diabetes and TVD were enrolled. The primary endpoint was all-cause death and the secondary endpoint was major adverse cardiac and cerebrovascular events (MACCE, composite of all-cause death, myocardial infarction, or stroke). RESULTS: During the mean follow-up of 6.3 ± 2.6 years, 573 (18.4%) deaths and 1094 (35.1%) MACCE occurred. Multivariate analysis showed that PCI (hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.32–0.51) and CABG (HR 0.33, 95% CI 0.26–0.44) were associated with a lower risk of death compared with MT, with no difference between the PCI and CABG groups. When MACCE was the endpoint, PCI (HR 0.71, 95% CI 0.60–0.84) and CABG (HR 0.48, 95% CI 0.39–0.57) had a lower risk than MT. CABG was associated with a significantly lower risk of MACCE compared with PCI (HR 0.67, 95% CI 0.55–0.81), which was mainly attributed a lower risk in myocardial infarction, but a higher risk of stroke. CONCLUSIONS: In this big real-world data and intermediate-term follow-up study, for patients with diabetes and TVD, PCI and CABG were associated with a lower risk of death and MACCE more than MT. The results suggest the importance of appropriate revascularization for diabetic patients with TVD. However, CABG was not associated with a lower risk of death, but with a lower risk of MACCE, compared with PCI. In the future, we perhaps should strengthen comprehensive treatment in addition to PCI or CABG.
format Online
Article
Text
id pubmed-7798318
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77983182021-01-12 Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3 years study from China Zhao, Xueyan Xu, Lianjun Jiang, Lin Tian, Jian Zhang, Yin Wang, Dong Sun, Kai Xu, Bo Zhao, Wei Hui, Rutai Gao, Runlin Song, Lei Yuan, Jinqing Cardiovasc Diabetol Original Investigation BACKGROUND: Patients with diabetes and triple-vessel disease (TVD) are associated with a high risk of events. The choice of treatment strategies remains a subject of discussion. In the real-world, we aim to compare the outcomes of medical therapy (MT), coronary artery bypass grafting (CABG), and percutaneous coronary intervention (PCI) treatment strategies in patients with diabetes and TVD. METHODS: A total of 3117 consecutive patients with diabetes and TVD were enrolled. The primary endpoint was all-cause death and the secondary endpoint was major adverse cardiac and cerebrovascular events (MACCE, composite of all-cause death, myocardial infarction, or stroke). RESULTS: During the mean follow-up of 6.3 ± 2.6 years, 573 (18.4%) deaths and 1094 (35.1%) MACCE occurred. Multivariate analysis showed that PCI (hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.32–0.51) and CABG (HR 0.33, 95% CI 0.26–0.44) were associated with a lower risk of death compared with MT, with no difference between the PCI and CABG groups. When MACCE was the endpoint, PCI (HR 0.71, 95% CI 0.60–0.84) and CABG (HR 0.48, 95% CI 0.39–0.57) had a lower risk than MT. CABG was associated with a significantly lower risk of MACCE compared with PCI (HR 0.67, 95% CI 0.55–0.81), which was mainly attributed a lower risk in myocardial infarction, but a higher risk of stroke. CONCLUSIONS: In this big real-world data and intermediate-term follow-up study, for patients with diabetes and TVD, PCI and CABG were associated with a lower risk of death and MACCE more than MT. The results suggest the importance of appropriate revascularization for diabetic patients with TVD. However, CABG was not associated with a lower risk of death, but with a lower risk of MACCE, compared with PCI. In the future, we perhaps should strengthen comprehensive treatment in addition to PCI or CABG. BioMed Central 2021-01-11 /pmc/articles/PMC7798318/ /pubmed/33430864 http://dx.doi.org/10.1186/s12933-020-01193-3 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Original Investigation
Zhao, Xueyan
Xu, Lianjun
Jiang, Lin
Tian, Jian
Zhang, Yin
Wang, Dong
Sun, Kai
Xu, Bo
Zhao, Wei
Hui, Rutai
Gao, Runlin
Song, Lei
Yuan, Jinqing
Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3 years study from China
title Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3 years study from China
title_full Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3 years study from China
title_fullStr Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3 years study from China
title_full_unstemmed Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3 years study from China
title_short Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3 years study from China
title_sort real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3 years study from china
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798318/
https://www.ncbi.nlm.nih.gov/pubmed/33430864
http://dx.doi.org/10.1186/s12933-020-01193-3
work_keys_str_mv AT zhaoxueyan realworldoutcomesofdifferenttreatmentstrategiesinpatientswithdiabetesandthreevesselcoronarydiseaseameanfollowup63yearsstudyfromchina
AT xulianjun realworldoutcomesofdifferenttreatmentstrategiesinpatientswithdiabetesandthreevesselcoronarydiseaseameanfollowup63yearsstudyfromchina
AT jianglin realworldoutcomesofdifferenttreatmentstrategiesinpatientswithdiabetesandthreevesselcoronarydiseaseameanfollowup63yearsstudyfromchina
AT tianjian realworldoutcomesofdifferenttreatmentstrategiesinpatientswithdiabetesandthreevesselcoronarydiseaseameanfollowup63yearsstudyfromchina
AT zhangyin realworldoutcomesofdifferenttreatmentstrategiesinpatientswithdiabetesandthreevesselcoronarydiseaseameanfollowup63yearsstudyfromchina
AT wangdong realworldoutcomesofdifferenttreatmentstrategiesinpatientswithdiabetesandthreevesselcoronarydiseaseameanfollowup63yearsstudyfromchina
AT sunkai realworldoutcomesofdifferenttreatmentstrategiesinpatientswithdiabetesandthreevesselcoronarydiseaseameanfollowup63yearsstudyfromchina
AT xubo realworldoutcomesofdifferenttreatmentstrategiesinpatientswithdiabetesandthreevesselcoronarydiseaseameanfollowup63yearsstudyfromchina
AT zhaowei realworldoutcomesofdifferenttreatmentstrategiesinpatientswithdiabetesandthreevesselcoronarydiseaseameanfollowup63yearsstudyfromchina
AT huirutai realworldoutcomesofdifferenttreatmentstrategiesinpatientswithdiabetesandthreevesselcoronarydiseaseameanfollowup63yearsstudyfromchina
AT gaorunlin realworldoutcomesofdifferenttreatmentstrategiesinpatientswithdiabetesandthreevesselcoronarydiseaseameanfollowup63yearsstudyfromchina
AT songlei realworldoutcomesofdifferenttreatmentstrategiesinpatientswithdiabetesandthreevesselcoronarydiseaseameanfollowup63yearsstudyfromchina
AT yuanjinqing realworldoutcomesofdifferenttreatmentstrategiesinpatientswithdiabetesandthreevesselcoronarydiseaseameanfollowup63yearsstudyfromchina